Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy

Marc J. Dubin, MD, PhD; Xiangling Mao, MS; Samprit Banerjee, PhD; Zachary Goodman, BS; Kyle A.B. Lapidus, MD; Guoxin Kang, PhD; Conor Liston, MD, PhD; Dikoma C. Shungu, PhD

**Introduction**

Transcranial magnetic stimulation (TMS) is an effective treatment for major depressive disorder (MDD), particularly in individuals resistant to first-line antidepressants.\(^1\)\(^-\)\(^3\) Effect sizes of TMS from recent meta-analyses range from 0.39 to 0.55.\(^4\)\(^,\)\(^5\) Less is known about the neurobiological mechanisms of antidepressant response to TMS. Emerging evidence suggests that in addition to its effects on the dorsolateral prefrontal cortex (DLPFC), TMS also affects structures to which the DLPFC projects, including the medial prefrontal cortex (MPFC).\(^6\) The MPFC is overactive in individuals with MDD,\(^7\) and functional connectivity between the DLPFC and MPFC predicts response to TMS.\(^8\)\(^-\)\(^10\) Little is known about how connectivity between the DLPFC and MPFC gives rise to the antidepressant effect of TMS.

Other antidepressants appear to act in part by modulating the excitability of cortical circuits. Levels of γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain, which are generally decreased in depressed individuals,\(^11\) have been reported to increase after treatment with selective serotonin reuptake inhibitors (SSRIs)\(^12\) and electroconvulsive therapy (ECT).\(^13\) Although TMS affects the balance of excitation and inhibition in cortical circuits,\(^14\) it is unknown whether changes in excitation-inhibition balance mediate antidepressant response.

In this naturalistic study, we tested whether TMS alters the levels of GABA and those of the combined resonance of glutamate and glutamine (Glx) in patients with MDD. Specifically, the standard J-edited spin echo difference proton magnetic resonance spectroscopy (\(^1\)H MRS) technique was implemented at 3 T to measure levels of MPFC GABA and Glx.
Glx before and after a 25-day course of 10-Hz TMS treatment over the left DLPFC. Based on the majority of reports in patients with MDD on the neurochemical response to antidepressant therapy,11,12,15 we hypothesized that TMS would selectively increase MPFC GABA levels while minimally affecting those of Glx.

Methods

Participants

Participants in this study were outpatients meeting DSM-IV-TR criteria for a nonpsychotic major depressive episode who provided written informed consent. Patients were referred by the outpatient clinic in the Department of Psychiatry at Weill Cornell Medical College, New York, USA. Also enrolled were self-referred patients who directly contacted our TMS program.

To be eligible, the patients were required to meet criteria for treatment-resistance, defined as a failure to respond to at least 2 previous antidepressant trials at adequate doses for at least 8 weeks during the current episode. Patients were also required to have a minimum score of 18 on the 24-item Hamilton Rating Scale for Depression (HAMD24). Patients were excluded if they were actively suicidal with plan or intent; were pregnant or lactating; had bipolar I disorder or a psychotic disorder; had been in their current episode for longer than 3 years; had a history of clinically significant personality disorder, as established in the diagnostic interview; or had a substance abuse disorder or substance dependence within the past 3 years, metal implants, a history of seizure disorder or other neurologic disorder, or a closed head injury with loss of consciousness.

Participants were allowed to continue prior medications, provided that the doses remained unchanged for 4 weeks before beginning the study and throughout the course of TMS. All aspects of our experimental protocol were approved by the Institutional Review Board of Weill Cornell Medical College and were conducted in accordance with federal and institutional human research guidelines.

Repetitive TMS protocol

All patients completed 25 sessions of rTMS over the left DLPFC over a 5-week period using the NeuroStar TMS Therapy System (Neuronetics, Inc.). We assessed treatment response using the HAMD24 at baseline and 1–3 days after completion of the 5-week course of treatment. Individual sessions consisted of 37.5 min (3000 pulses; 30-s duty cycle, 4 s on, 26 s off) of 10-Hz excitatory TMS daily for 25 days (Monday–Friday for a 5-week period). The standard “Figure 8” NeuroStar TMS coil was centred over the scalp via the Beam F3 method16 using surface distances between the nasion, inion, tragus and vertex as landmarks. Resting motor threshold (MT) was defined as the stimulus strength over the mean MT, and applied intensities of 80%–120% (mean 86.4% ± 14.3%) to all participants except for 2, who reported scalp pain above an intensity of 80% of resting MT. Resting MT and stimulation intensity for each participant are described in Appendix 1, Table S2, available at jpn.ca.

Magnetic resonance neuroimaging procedures

All neuroimaging studies, which included limited structural brain MRI examination and single-voxel 1H MRS of the MPFC, were conducted on a research-dedicated 3.0 T GE MR system with an 8-channel phased-array head coil at the CitiGroup Biomedical Imaging Center of Weill Cornell Medical College. All patients underwent 2 neuroimaging sessions that occurred before (mean 2.5 ± 2.3 d) and shortly after (mean 1.0 ± 1.1 d) completing the 5-week course of TMS.

Structural MRI

A 3-plane, low-resolution, high-speed scout imaging series was obtained, followed by a series of high-resolution scans, consisting of standard axial, coronal and sagittal T₁-, T₂- and spin density-weighted scans that were appropriately obliqued for prescribing the 1H MRS voxel in the MPFC. In addition, we obtained a T₁-weighted spoiled gradient-recalled echo (SPGR) volumetric scan and an axial Fast Fluid-Attenuated Inversion Recovery (FLAIR) scan for brain tissue segmentation and detection of exclusionary focal brain lesions, respectively.

1H MRS

The GABA-edited 1H MRS data were acquired using the standard J-edited spin echo difference method17 and then processed as described recently16,18 (Fig. 1, Appendix 1). Each spectrum was recorded from a single 2.5 × 2.5 × 3.0 cm voxel prescribed in the MPFC, which includes a rostral component of the anterior cingulate cortex (Fig. 1A and B).

1H MRS data processing and quantitation

Details of the MRS data quality assessment criteria and procedures used in this study to retain or reject spectra for inclusion in group analyses are provided in Appendix 1. For all the cases that fulfilled our quality assessment criteria, spectral peak areas, which are proportional to the concentrations of the associated metabolites, were obtained as illustrated in Fig. 1C (traces [a-f]). Briefly, the GABA and Glx resonances in the J-edited difference spectra were modelled as a linear combination of pseudo-Voigt lineshape functions and then fitted in the frequency domain using a robust and highly optimized public-domain Levenberg–Marquardt nonlinear least squares minimization routine.15 For normalization across participants, the GABA and Glx levels were expressed as ratios of peak areas relative to the area of the synchronously acquired and similarly fitted unsuppressed voxel water signal (W).
Assessment of voxel tissue heterogeneity

To estimate the proportions of grey matter, white matter and cerebrospinal fluid (CSF) contained in each voxel of interest, we used MEDx software (Medical Numerics) to segment the brain tissue based on the signal-intensity histogram of each participant’s volumetric (SPGR) MRI. In-house software developed in MATLAB (MathWorks) was then implemented to generate a segmentation mask for each voxel, from which the proportions of grey matter, white matter and CSF were determined. These were then compared between baseline and post-TMS for the whole group and, in case of significant differences, included in the statistical model as covariates.

Statistical analysis

A TMS responder was defined as having at least a 50% reduction in HAMD24 scores post-TMS compared with baseline.

![Fig. 1: (A, B) Magnetic resonance images showing medial prefrontal cortex (MPFC) voxel size and location. (C) J-editing spectra obtained using volume-selective point-resolved spectroscopy (PRESS) with the editing radiofrequency pulse (a) on and (b) off. (c) The difference of the spectra in (a) and (b), showing (c) the edited γ-aminobutyric acid (GABA) and combined resonance of glutamate and glutamine (Glx) peaks, with (d) best-fit model spectrum of (c), and (e) the residuals of the difference between the edited (c) and best-fit (d) spectra. The data were acquired in 13 min from a 2.5 × 2.5 × 3.0 cm³ voxel using an echo time (TE) of 68 ms and a repetition time (TR) of 1500 ms, and 256 interleaved excitations (512 total) with editing pulse on or off.](image)
To test our 2 primary hypotheses, we used a paired $t$ test or Wilcoxon signed rank test wherever appropriate to compare GABA/W and Glx/W before and after TMS in all participants. In an exploratory analysis, we used linear regression to assess the effect of independent variables, including TMS-responder status, age, sex, baseline HAMD score, TMS intensity (% of resting MT), history of antipsychotic or mood stabilizer use, lifetime number of antidepressant trials, current benzodiazepine use (lorazepam equivalents in milligrams), and current SSRI use on 2 dependent variables: percent change in GABA/W and in Glx/W from before to after TMS. Stepwise variable selection with the Akaike Information Criterion was used to select the best-fitting set of independent variables. We performed linear regression to test for potential linear associations between neurotransmitter levels (GABA/W and Glx/W) and the severity of depressive symptoms. All reported $p$ values are 2-tailed at $\alpha = 0.05$ except the primary hypotheses, where $\alpha = 0.025$ after adjusting for multiple comparisons using the Bonferroni method. We used IBM SPSS Statistics version 22 and R software version 3.1.1 to perform all the statistical analyses.

**Results**

**Demographics and sample characteristics**

In the aggregate, 25 patients with treatment-resistant depression were enrolled in this study, and all completed the 5-week course of TMS. Data for 2 patients were excluded from all the analyses owing to significant differences in head tilt in the magnet between the baseline and post-TMS neuroimaging scans, leaving 23 outpatients for subsequent analyses: 21 with MDD, 2 with bipolar II disorder (mean age $41.7 \pm 15.9$ yr; 7 [30%] men). The clinical and demographic characteristics of the final sample before and after the 5-week course of TMS are summarized in Table 1.

The mean lifetime number of major depressive episodes was $4.9 \pm 2.4$. Two participants had a history of hypomania and thus met a diagnosis of bipolar II disorder. Four patients had psychiatric comorbidities: 1 had attention-deficit/hyperactivity disorder, 2 had obsessive-compulsive disorder and 1 had generalized anxiety disorder. Of the 23 patients included in the final sample, 19 (83%) were taking antidepressants, and a number were taking mood stabilizers, antipsychotics, or other medications (Appendix 1, Table S1).

**Effects of TMS treatment on depressive symptoms**

On average, patients’ depressive symptoms, as assessed using the HAMD24, improved by 9.9 points (from 28.7 to 18.8) from the first to the final TMS treatment sessions (95% confidence interval [CI] –9.0 to –4.3). Depressive symptoms in the 8 responders improved on average by 17.6 points (from 28.1 to 10.5) from the first to the final TMS treatment sessions (95% CI –12.1 to –7.5). In contrast (and by definition), depressive symptoms did not improve in the 15 nonresponders, changing on average by 5.9 points (from 29.1 to 23.2) from the first to the final TMS treatment sessions (95% CI –4.2 to 0.8).

**$^1$H MRS voxel tissue heterogeneity**

Table 2 provides the proportions of grey matter, white matter and CSF in the MPFC voxel for baseline and post-TMS, as determined by tissue segmentation, as well as the mean unsuppressed voxel tissue water signal (W) for baseline and post-TMS. Using paired $t$ tests, we detected no differences in

---

**Table 1. Demographic and clinical characteristics of study participants**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All MDD, n = 23</th>
<th>TMS responders, n = 8</th>
<th>TMS nonresponders, n = 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>$41.7 \pm 15.9$ [21–68]</td>
<td>$37.0 \pm 16.1$ [23–66]</td>
<td>$44.2 \pm 15.8$ [21–68]</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7 (30.4)</td>
<td>2 (25)</td>
<td>5 (33)</td>
</tr>
<tr>
<td>Female</td>
<td>16 (69.6)</td>
<td>6 (75)</td>
<td>10 (67)</td>
</tr>
<tr>
<td>Illness history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episode duration, mo</td>
<td>$14.5 \pm 10.1$ [2–36]</td>
<td>$17.4 \pm 11.6$ [3–36]</td>
<td>$12.9 \pm 9.2$ [2–36]</td>
</tr>
<tr>
<td>No. of episodes</td>
<td>$4.9 \pm 2.4$ [2–10]</td>
<td>$4.4 \pm 2.3$ [2–8]</td>
<td>$5.1 \pm 2.4$ [2–10]</td>
</tr>
<tr>
<td>Suicide attempts</td>
<td>$0.7 \pm 1.0$ [0–4]</td>
<td>$0.9 \pm 0.8$ [0–2]</td>
<td>$0.6 \pm 1.1$ [0–4]</td>
</tr>
<tr>
<td>Psychiatric hospitalizations</td>
<td>$1.4 \pm 1.6$ [0–5]</td>
<td>$0.6 \pm 0.7$ [0–2]</td>
<td>$1.8 \pm 1.7$ [0–5]</td>
</tr>
<tr>
<td>Medication-naive</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Medication-free</td>
<td>4 (17)</td>
<td>3 (38)</td>
<td>1 (7)</td>
</tr>
<tr>
<td>HAMD24 baseline</td>
<td>$28.7 \pm 5.6$ [18–39]</td>
<td>$28.1 \pm 6.1$ [22–37]</td>
<td>$29.1 \pm 5.5$ [18–39]</td>
</tr>
<tr>
<td>HAMD24 final</td>
<td>$18.8 \pm 8.2$ [3–37]</td>
<td>$10.5 \pm 5.0$ [3–17]</td>
<td>$23.2 \pm 5.7$ [15–37]</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADHD</td>
<td>1 (4)</td>
<td>1 (12.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Any anxiety disorder</td>
<td>3 (13)</td>
<td>1 (12.5)</td>
<td>2 (13)</td>
</tr>
</tbody>
</table>

ADHD = attention-deficit/hyperactivity disorder; HAMD24 = 24-item Hamilton Rating Scale for Depression; MDD = major depressive disorder; SD = standard deviation; TMS = transcranial magnetic stimulation.
Elevated prefrontal cortex GABA in patients with MDD

percentage of grey matter ($t_g = 0.69$, $p = 0.49$), percentage of white matter ($t_w = 1.10$, $p = 0.28$), or percentage of CSF ($t_w = 0.80$, $p = 0.44$) between baseline and post-TMS for the whole group. Levels of the reference voxel water signal did not differ from baseline to post-TMS for the whole group ($t_w = 0.35$, $p = 0.73$). Therefore, we henceforth use simply GABA or Glx to mean GABA/W or Glx/W, respectively.

**Primary hypothesis: GABA and Glx levels before and after TMS treatment**

In all participants (Fig. 2A), the mean MPFC GABA level was higher post-TMS than at baseline ($2.98 \times 10^{-3} \pm 0.60 \times 10^{-3}$ vs. $2.66 \times 10^{-3} \pm 0.53 \times 10^{-3}$, mean change in GABA 13.8%, paired $t_w = 2.66$, $p = 0.023$). Among responders, there was a significantly higher mean MPFC GABA level post-TMS than at baseline ($3.08 \times 10^{-3} \pm 0.60 \times 10^{-3}$ vs. $2.68 \times 10^{-3} \pm 0.66 \times 10^{-3}$, mean change in GABA 17.4%, Wilcoxon $V = 2$, $p = 0.023$). Among nonresponders, there was a trend toward higher mean MPFC GABA levels post-TMS than at baseline ($2.92 \times 10^{-3} \pm 0.61 \times 10^{-3}$ vs. $2.65 \times 10^{-3} \pm 0.45 \times 10^{-3}$, mean change in GABA 11.9%, Wilcoxon $V = 26$, $p = 0.06$).

If response was defined more liberally as a greater than 30% reduction in HAMD24 scores, there were 12 responders and 11 nonresponders. Among responders, there was a significantly higher mean MPFC GABA level post-TMS than at baseline ($3.03 \times 10^{-3} \pm 0.61 \times 10^{-3}$ vs. $2.63 \times 10^{-3} \pm 0.62 \times 10^{-3}$, mean change in GABA 17.4%, Wilcoxon $V = 2$, $p = 0.001$).

Among nonresponders, MPFC GABA levels post-TMS were greater than at baseline ($2.92 \times 10^{-3} \pm 0.61 \times 10^{-3}$ vs. $2.70 \times 10^{-3} \pm 0.44 \times 10^{-3}$); this difference was smaller than in responders and was nonsignificant (mean change in GABA 9.9%, Wilcoxon $V = 18$, $p = 0.21$).

The presence of a psychiatric comorbidity influenced the magnitude of change of post-TMS GABA from baseline. One participant in the responder group (defined by 50% reduction in HAMD24 score) had a comorbid disorder (ADHD), and 5 participants in the nonresponder group had comorbidities (2 had bipolar II Disorder, 2 had obsessive-compulsive disorder and 1 had generalized anxiety disorder). The 1 responder with ADHD had a large (55%) increase in post-TMS GABA from baseline, which significantly impacted the average GABA increase in the responder group. Among the 7 responders without comorbidities, there was a significantly higher mean MPFC GABA level post-TMS (mean change in GABA 12.0%, Wilcoxon $V = 2$, $p = 0.047$). Among nonresponders, MPFC GABA levels post-TMS were also larger than at baseline, although this difference did not reach significance (mean change in GABA 10.9%, Wilcoxon $V = 11$, $p = 0.11$).

**Table 2: GABA/W concentration, grey matter, white matter, and CSF percentages before and after TMS**

<table>
<thead>
<tr>
<th>Measure; group</th>
<th>Timing; mean ± SD or no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-TMS</td>
</tr>
<tr>
<td>All participants, $n = 23$</td>
<td></td>
</tr>
<tr>
<td>ACC GABA/W</td>
<td>$2.66 \times 10^{-3} \pm 0.53 \times 10^{-3}$</td>
</tr>
<tr>
<td>ACC Glx/W</td>
<td>$2.14 \times 10^{-3} \pm 0.41 \times 10^{-3}$</td>
</tr>
<tr>
<td>ACC water</td>
<td>$1.75 \times 10^{-3} \pm 0.52 \times 10^{-3}$</td>
</tr>
<tr>
<td>Grey matter</td>
<td>53.1 (2.8)</td>
</tr>
<tr>
<td>White matter</td>
<td>31.5 (2.9)</td>
</tr>
<tr>
<td>CSF</td>
<td>15.4 (2.1)</td>
</tr>
<tr>
<td>TMS responders, $n = 8$</td>
<td></td>
</tr>
<tr>
<td>ACC GABA/W</td>
<td>$2.68 \times 10^{-3} \pm 0.66 \times 10^{-3}$</td>
</tr>
<tr>
<td>ACC Glx/W</td>
<td>$1.98 \times 10^{-3} \pm 0.44 \times 10^{-3}$</td>
</tr>
<tr>
<td>ACC water</td>
<td>$1.71 \times 10^{-3} \pm 0.47 \times 10^{-3}$</td>
</tr>
<tr>
<td>Grey matter</td>
<td>51.4 (2.3)</td>
</tr>
<tr>
<td>White matter</td>
<td>32.3 (1.9)</td>
</tr>
<tr>
<td>CSF</td>
<td>16.3 (1.0)</td>
</tr>
<tr>
<td>TMS nonresponders, $n = 15$</td>
<td></td>
</tr>
<tr>
<td>ACC GABA/W</td>
<td>$2.65 \times 10^{-3} \pm 0.48 \times 10^{-3}$</td>
</tr>
<tr>
<td>ACC Glx/W</td>
<td>$2.23 \times 10^{-3} \pm 0.38 \times 10^{-3}$</td>
</tr>
<tr>
<td>ACC water</td>
<td>$1.77 \times 10^{-3} \pm 0.56 \times 10^{-3}$</td>
</tr>
<tr>
<td>Grey matter</td>
<td>53.9 (2.7)</td>
</tr>
<tr>
<td>White matter</td>
<td>31.3 (3.3)</td>
</tr>
<tr>
<td>CSF</td>
<td>15.0 (2.5)</td>
</tr>
</tbody>
</table>

ACC = anterior cingulate cortex; CSF = cerebrospinal fluid; GABA/W = γ-aminobutyric acid level relative to unsuppressed voxel tissue water; Glx = combined resonance of glutamate and glutamine; SD = standard deviation; TMS = transcranial magnetic stimulation.

*Significantly increased ACC GABA in the whole group before compared with after TMS ($p = 0.01$).
In all participants (Fig. 2B), mean MPFC Glx levels were unchanged post-TMS relative to baseline (2.15 × 10^{-3} ± 0.43 × 10^{-3} v. 2.14 × 10^{-3} ± 0.41 × 10^{-3}, paired t_22 = 0.05 p = 0.96). Among responders, mean MPFC Glx levels were unchanged post-TMS relative to baseline (2.16 × 10^{-3} ± 0.32 × 10^{-3} v. 1.98 × 10^{-3} ± 0.44 × 10^{-3}, Wilcoxon V = 11, p = 0.38). Similarly, among nonresponders, mean MPFC Glx levels were unchanged post-TMS relative to baseline (2.14 × 10^{-3} ± 0.49 × 10^{-3} v. 2.23 × 10^{-3} ± 0.38 × 10^{-3}, Wilcoxon V = 75, p = 0.42). Mean MPFC Glx levels remained unchanged when we used the definition of a response of greater than 30% reduction in HAMD24 score and when we removed participants with psychiatric comorbidities from our analyses.

Demographic variables versus GABA and Glx levels before and after TMS

Regression analysis of percent change in GABA with stepwise selection retained age, sex, current SSRI use and daily lorazepam use as predictors, and the model had an adjusted R^2 value of 0.31. Percent GABA change was significantly and positively associated with age (t = 2.15, p = 0.046) and male sex (t = 2.59, p = 0.018) and showed a trend toward significance for a negative association with current use of SSRI (t = –2.09, p = 0.05) and current daily use of lorazepam (t = –1.81, p = 0.09)

Percent change in GABA was not associated with baseline HAMD24 score, TMS responder status, TMS intensity, lifetime number of antidepressant trials, or history of antipsychotic or mood stabilizer use.

Exploratory analysis: MPFC GABA versus Glx correlations before and after TMS

Given that metabolic GABA is synthesized from glutamate by the enzyme L-glutamic acid decarboxylase (GAD) and that the GABA shunt converts to glutamate, it is generally of interest to explore associations between the 2 neurotransmitters, especially since they both are postulated to play an important role in many neuropsychiatric disorders, including MDD. Our exploratory investigation of such associations revealed GABA to correlate strongly with Glx in participants with severe depression (i.e., HAMD24 > 27, n = 11) at baseline (r = 0.90, p < 0.001; Fig. 3A), but not in patients with moderate depression (HDRD24 < = 27, n = 12, r = 0.06, p = 0.86; Fig. 3B). Post-TMS, GABA and Glx were uncorrelated (r = 0.35, p = 0.29) in the severe depression group (Fig. 3C), with still no GABA and Glx correlation (r = 0.10, p = 0.77) in the moderate depression group (Fig. 3D).

Discussion

The novelty of our study is its focus on examining changes in brain GABA and Glx levels in patients with depression before and after a course of therapeutic TMS. We found GABA elevations in the MPFC post-TMS relative to levels at baseline in a cohort of adults with MDD. The GABA elevations were greater in responders than in nonresponders (17.4% v. 11.9%). Differences between responders and nonresponders were more pronounced (17.4% v. 9.9%) if response was defined

![Fig. 2: γ-Aminobutyric acid/unsuppressed voxel water signal (GABA/W) levels in the medial prefrontal cortex (MPFC) in depressed patients before and after a 25-session treatment with transcranial magnetic stimulation (TMS) over the left dorsolateral prefrontal cortex (DLPFC). Each graph shows GABA levels for the sample both at baseline (pre-) and post-TMS. (A) Full sample of 23 participants. Average GABA/W increases by 13.8% (p = 0.007). (B) Subgroup of TMS responders. GABA/W increases by 17.4% post-TMS compared with baseline (p = 0.013). In the subgroup of TMS nonresponders there was an 11.9% change in GABA/W post-TMS compared with baseline (p = 0.07). Glx = combined resonance of glutamate and glutamine; NS = nonsignificant.](image-url)
Elevated prefrontal cortex GABA in patients with MDD

more liberally as a greater than 30% reduction in HAMD24 scores. In contrast, we found no differences or changes in Glx between baseline and post-TMS.

The main result of the present study, that the antidepressant effect of rTMS was associated with elevation of GABA levels relative to baseline, is consistent with and extends prior observations about GABA in depression and the effects of antidepressant treatments. The observed increase in GABA was also seen in nonresponders, suggesting that GABA increase may contribute to the antidepressant mechanism of TMS, but this association was not causal. Levels of GABA are low in the depressed brain, supported by convergent evidence from CSF samples, GABAergic neuronal density and GAD67 expression in postmortem brains. Prior MRS studies revealed GABA reductions in depressed individuals compared with healthy controls, with more pronounced MPFC reductions in a treatment-refractory subgroup. Further, and also in support of the GABA-deficit hypothesis of depression, a variety of different antidepressants seem to function, in part, by elevating GABA. These include SSRIs, the monoamine-oxidase inhibitor phenelzine, the GABA-reuptake inhibitor tiagabine and ECT.

We did not observe changes in Glx levels, either in the whole group or in TMS-responder or nonresponder subgroups. Glx levels have been found to be reduced in the MPFC at baseline in patients with depression, and these levels have normalized in the lateral prefrontal cortex, MPFC and amygdala after ECT; in the DLPFC after TMS for pediatric depression; and in the anterior cingulate cortex in healthy individuals after TMS. The difference between our findings and those previously reported in healthy individuals after TMS may reflect a difference in Glx homeostasis in the MPFC in patients with depression.

Fig. 3: γ-Aminobutyric acid/unsuppressed voxel water signal (GABA/W) in the medial prefrontal cortex (MPFC) plotted by depression severity (first and second rows) and baseline and post–transcranial magnetic stimulation (TMS; first and second columns). (A) GABA/W and combined resonance of glutamate and glutamine (Glx)/W are tightly correlated in severely depressed patients at baseline ($r = 0.90$, $p < 0.001$) and (B) uncorrelated in moderately depressed patients ($r = 0.06$, $p = 0.86$). (C) In patients who were severely depressed before treatment, this correlation was reduced post-TMS ($r = 0.35$, $p = 0.29$). (D) GABA/W and Glx/W remained uncorrelated in moderately depressed patients post-TMS ($r = 0.10$, $p = 0.77$). MDD = major depressive disorder.
As already suggested, GABA elevation in the MPFC may contribute to the antidepressant mechanism of TMS. Optogenetic studies in rodents indicate that homeostasis in the ratio of excitation to inhibition in MPFC microcircuits plays a critical role in supporting normal circuit function and PFC-dependent behaviours. In patients, GABA deficits may contribute to findings of MPFC hyperactivity and elevated functional connectivity that have been reported in patients with depression, all of which have been shown to normalize after antidepressant treatment with SSRIs, TMS, ECT and deep brain stimulation. The lack of increase of Glx after TMS may highlight a seizure-dependent antidepressant mechanism specific to ECT suggested by postictal elevations. TMS may highlight a seizure-dependent antidepressant treatment with SSRIs, ECT and ECT, which has dense reciprocal connections with the DLPFC. This may indicate both restoration of GABAergic synapses as well as improved homeostatic connections with the potentially excitotoxic glutamatergic system. Future studies should elucidate whether these neurochemical changes mediate plasticity of the resting-state networks that show elevated functional connectivity in patients with depression.

Limitations

Our study has several limitations. First, it is a naturalistic study, and the lack of a group of healthy controls makes it difficult to determine if the change in GABA reflected normalization of a GABA deficit or an elevation above the normal level. Second, the heterogeneity of our patient population and their concurrent medication treatment raises a potential confound between different causes of GABA elevation. While our inclusion of currently depressed patients with bipolar II disorder may be considered another limitation of this study since it increases sample heterogeneity, this is mitigated by the fact that studying individuals with symptom clusters that may cross diagnostic boundaries is in line with the new US National Institute of Mental Health Research Domain Criteria (RDoC) framework for studying mental disorders. Current SSRI and benzodiazepine use were negatively associated with increase in GABA, suggesting that treatment with these medications may have partially prevented GABA elevations in a subgroup of participants. Third, owing to discomfort, some participants could not be treated at the standard stimulus strength of 120% of MT. Finally, a general limitation related to 1H MRS is the inability of the standard J-editing method to separate glutamate from glutamine, yielding the composite resonance that is commonly referred to as “Glx.” However, we recently obtained preliminary evidence that strongly suggests that the J-edited Glx peak consists primarily of glutamate, with little or no glutamine contribution.

Conclusion

The major inhibitory neurotransmitter system represented by GABA is at the intersection of the pathophysiology of depression as well as mechanisms of its treatment. Transcranial magnetic stimulation over the left DLPFC improves depressive symptoms, and this is correlated with selective elevations of GABA in the MPFC, which has dense reciprocal connections with the DLPFC. This may indicate both restoration of GABAergic synapses as well as improved homeostatic connections with the potentially excitotoxic glutamatergic system. Future studies should elucidate whether these neurochemical changes mediate plasticity of the resting-state networks that show elevated functional connectivity in patients with depression.

Acknowledgements

The authors thank Rebecca Gordon and Jude Allen for technical assistance in administering transcranial magnetic stimulation and Rebecca Gordon for administering the Hamilton Rating Scales for Depression.

Affiliations

From the Department of Psychiatry, Weill Cornell Medical College, New York, USA (Dubin, Liston); the Brain and Mind Research Institute, Weill Cornell Medical College, New York, USA (Dubin, Liston); the Department of Radiology, Weill Cornell Medical College, New York, USA (Mao, Kang, Shungu); the Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, USA (Banerjee); the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA (Lapidus); and the Johns Hopkins University, Baltimore, USA (Goodman).

Funding: Research reported in this publication was supported by the Office of the Director, National Institutes of Health under Award Number S10OD021782. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by grants from the Brain and Behavior Research Foundation (National Alliance for Research on Schizophrenia and Depression Young Investigator Award) to M. Dubin and by funds from the Department of Psychiatry at Weill Cornell Medical College. C. Liston was supported by grants from the National Institutes of Health (K99 MH109782) and the DeWitt Wallace Reader’s Digest Foundation at Weill Cornell. These sources of funding had no further role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Competing interests: M. Dubin reports receiving a materials transfer from Neuronetics, Inc to complete this study, but received no compensation from Neuronetics. K. Lapidus serves on the advisory board for Halo Neuro, Inc., has received devices from Medtronic and Brainway, and consults for LCN Consulting, Inc. No other competing interests declared.

Contributors: M. Dubin and D. Shungu designed the study. M. Dubin, X. Mao, Z. Goodman and D. Shungu acquired the data, which M. Dubin, X. Mao, S. Banerjee, K. Lapidus, G. Kang, C. Liston and D. Shungu analyzed. M. Dubin, S. Banerjee, K. Lapidus, C. Liston and D. Shungu wrote the article, which all authors reviewed and approved for publication.

References

Elevated prefrontal cortex GABA in patients with MDD


5. Slotema CW, Blom JD, Hoek HW, et al. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. *J Clin Psychiatry* 2010;71:873-84.


44. Shungu DC. Demystifying the “Glx” peak that co-edits with GABA by *J-editing*. *Cardiff, Wales, UK; 2013.